Avalo Therapeutics is developing a high affinity IL-1β for hidradenitis suppurativa - key phase 2 data will come next year

CEO Garry Neil describes the target and how he believes Avalo's therapy has especially high affinity. Approximately 1% of the population is believe to have HS.